--Novel Transmitter Will Simplify Artificial Pancreas Research by Eliminating a Separate CGM component-- NEW YORK, April 24, 2012 /PRNewswire-USNewswire/ -- JDRF, the leading

WEST CHESTER, Pa., June 2, 2011 - Animas Corporation announced today the receipt of CE Mark approval for Animas® Vibe(TM), the first and only continuous glucose monitoring (CGM)-enabled insulin pump system with Dexcom G4(TM) CGM technology.

New study data presented by the Juvenile Diabetes Research Foundation (JDRF) today at the 44th annual meeting of the European Association for the Study of Diabetes (EASD), showed the use of Continuous Glucose Monitoring (CGM) to be effective in the management of Type 1 Diabetes.

DexCom Inc. (NASDAQ:DXCM) today announced the appointment of Jonathan T. Lord, M.D. as a member of DexCom's Board of Directors. Dr. Lord currently serves as Senior Vice President and Chief Innovation Officer for Humana Inc., a health benefits company. Dr.

DexCom, Inc. (NASDAQ: DXCM), a leading provider of